These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

143 related articles for article (PubMed ID: 34766555)

  • 21. Detection of NTRK fusions in glioblastoma: fluorescent in situ hybridisation is more useful than pan-TRK immunohistochemistry as a screening tool prior to RNA sequencing.
    Bourhis A; Caumont C; Quintin-Roué I; Magro E; Dissaux G; Remoué A; Le Noac'h P; Douet-Guilbert N; Seizeur R; Tyulyandina A; Schick U; Merlio JP; Marcorelles P; Cappellen D; Uguen A
    Pathology; 2022 Feb; 54(1):55-62. PubMed ID: 34518039
    [TBL] [Abstract][Full Text] [Related]  

  • 22. In silico validation of RNA-Seq results can identify gene fusions with oncogenic potential in glioblastoma.
    Hernandez A; Muñoz-Mármol AM; Esteve-Codina A; Alameda F; Carrato C; Pineda E; Arpí-Lluciá O; Martinez-García M; Mallo M; Gut M; Del Barco S; Gallego O; Dabad M; Mesia C; Bellosillo B; Domenech M; Vidal N; Aldecoa I; de la Iglesia N; Balana C
    Sci Rep; 2022 Aug; 12(1):14439. PubMed ID: 36002559
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Coexisting FGFR3 p.K650T mutation in two FGFR3-TACC3 fusion glioma cases.
    Ballester LY; Moghadamtousi SZ; Leeds NE; Huse JT; Fuller GN
    Acta Neuropathol Commun; 2019 Apr; 7(1):63. PubMed ID: 31036092
    [No Abstract]   [Full Text] [Related]  

  • 24. Can adult
    Gilani A; Davies KD; Kleinschmidt-DeMasters BK
    Clin Neuropathol; 2021; 40(3):165-167. PubMed ID: 33769273
    [No Abstract]   [Full Text] [Related]  

  • 25. Enhanced expression and phosphorylation of the MET oncoprotein by glioma-specific PTPRZ1-MET fusions.
    Chen HM; Yu K; Tang XY; Bao ZS; Jiang T; Fan XL; Chen XW; Su XD
    FEBS Lett; 2015 Jun; 589(13):1437-43. PubMed ID: 25935522
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Infiltrating gliomas with FGFR alterations: Histologic features, genetic alterations, and potential clinical implications.
    Dono A; El Achi H; Bundrant BE; Goli PS; Zhu P; Ozkizilkaya HI; Esquenazi Y; Ballester LY
    Cancer Biomark; 2023; 36(2):117-131. PubMed ID: 36530080
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Multiple functions of a glioblastoma fusion oncogene.
    Babic I; Mischel PS
    J Clin Invest; 2013 Feb; 123(2):548-51. PubMed ID: 23298839
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Prevalence of NTRK Fusions in Canadian Solid Tumour Cancer Patients.
    Silvertown JD; Lisle C; Semenuk L; Knapp C; Jaynes J; Berg D; Kaul N; Lachapelle J; Richardson L; Speevak M; Sarras H; Berman DM; Carter R; Feilotter H; Feltis T
    Mol Diagn Ther; 2023 Jan; 27(1):87-103. PubMed ID: 36194351
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Recurrent MET fusion genes represent a drug target in pediatric glioblastoma.
    International Cancer Genome Consortium PedBrain Tumor Project
    Nat Med; 2016 Nov; 22(11):1314-1320. PubMed ID: 27748748
    [TBL] [Abstract][Full Text] [Related]  

  • 30. FGFR3-TACC3 fusion in solid tumors: mini review.
    Costa R; Carneiro BA; Taxter T; Tavora FA; Kalyan A; Pai SA; Chae YK; Giles FJ
    Oncotarget; 2016 Aug; 7(34):55924-55938. PubMed ID: 27409839
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Clinical, molecular, and radiomic profile of gliomas with FGFR3-TACC3 fusions.
    Di Stefano AL; Picca A; Saragoussi E; Bielle F; Ducray F; Villa C; Eoli M; Paterra R; Bellu L; Mathon B; Capelle L; Bourg V; Gloaguen A; Philippe C; Frouin V; Schmitt Y; Lerond J; Leclerc J; Lasorella A; Iavarone A; Mokhtari K; Savatovsky J; Alentorn A; Sanson M;
    Neuro Oncol; 2020 Nov; 22(11):1614-1624. PubMed ID: 32413119
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Diffuse Gliomas with FGFR3-TACC3 Fusions: Oncogenic Mechanisms, Hallmarks, and Therapeutic Perspectives.
    Picca A; Sansone G; Santonocito OS; Mazzanti CM; Sanson M; Di Stefano AL
    Cancers (Basel); 2023 Nov; 15(23):. PubMed ID: 38067258
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Identification of a novel KLC1-ROS1 fusion in a case of pediatric low-grade localized glioma.
    Nakano Y; Tomiyama A; Kohno T; Yoshida A; Yamasaki K; Ozawa T; Fukuoka K; Fukushima H; Inoue T; Hara J; Sakamoto H; Ichimura K
    Brain Tumor Pathol; 2019 Jan; 36(1):14-19. PubMed ID: 30350109
    [TBL] [Abstract][Full Text] [Related]  

  • 34. IDH-mutant gliomas with additional class-defining molecular events.
    Ahrendsen JT; Torre M; Meredith DM; Hornick JL; Reardon DA; Wen PY; Yeo KK; Malinowski S; Ligon KL; Ramkissoon S; Alexandrescu S
    Mod Pathol; 2021 Jul; 34(7):1236-1244. PubMed ID: 33772213
    [TBL] [Abstract][Full Text] [Related]  

  • 35. [NTRK Fusions: A new way of treatment for gastro-intestinal tumor?].
    Ouali K; Pellat A; Cohen R; Svrcek M; Penault-Llorca F; André T
    Bull Cancer; 2020 Apr; 107(4):447-457. PubMed ID: 32067719
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Rare but Recurrent ROS1 Fusions Resulting From Chromosome 6q22 Microdeletions are Targetable Oncogenes in Glioma.
    Davare MA; Henderson JJ; Agarwal A; Wagner JP; Iyer SR; Shah N; Woltjer R; Somwar R; Gilheeney SW; DeCarvalo A; Mikkelson T; Van Meir EG; Ladanyi M; Druker BJ
    Clin Cancer Res; 2018 Dec; 24(24):6471-6482. PubMed ID: 30171048
    [TBL] [Abstract][Full Text] [Related]  

  • 37. FGFR-TACC gene fusions in human glioma.
    Lasorella A; Sanson M; Iavarone A
    Neuro Oncol; 2017 Apr; 19(4):475-483. PubMed ID: 27852792
    [TBL] [Abstract][Full Text] [Related]  

  • 38. MiR-1261/circ-PTPRZ1/PAK1 pathway regulates glioma cell growth and invasion.
    Zhang F; Mai SR; Cao FP; Cao CX; Zhang L
    Hum Cell; 2019 Oct; 32(4):540-547. PubMed ID: 31364003
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Emergence of FGFR3-TACC3 fusions as a potential by-pass resistance mechanism to EGFR tyrosine kinase inhibitors in EGFR mutated NSCLC patients.
    Ou SI; Horn L; Cruz M; Vafai D; Lovly CM; Spradlin A; Williamson MJ; Dagogo-Jack I; Johnson A; Miller VA; Gadgeel S; Ali SM; Schrock AB
    Lung Cancer; 2017 Sep; 111():61-64. PubMed ID: 28838400
    [TBL] [Abstract][Full Text] [Related]  

  • 40. FGFR3, as a receptor tyrosine kinase, is associated with differentiated biological functions and improved survival of glioma patients.
    Wang Z; Zhang C; Sun L; Liang J; Liu X; Li G; Yao K; Zhang W; Jiang T
    Oncotarget; 2016 Dec; 7(51):84587-84593. PubMed ID: 27829236
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 8.